Medullary carcinoma of the colon: can the undifferentiated be differentiated?

Virchows Archiv

Volumn 466, Issue 1, 2015, Pages 13-20

  Fiehn, Anne Marie Kanstrup ^a   Grauslund, Morten ^a   Glenthøj, Anders ^a   Melchior, Linea Cecilie ^a   Vainer, Ben ^a,b   Willemoe, Gro Linno ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Immunohistochemical profile; Interobserver agreement; Medullary carcinoma; MLH 1; Molecular profile

Indexed keywords

B RAF KINASE; CALRETININ; CHROMOGRANIN; CYTOKERATIN 20; CYTOKERATIN 7; K RAS PROTEIN; MISMATCH REPAIR PROTEIN PMS2; MUCIN 1; MUCIN 2; MUCIN 5AC; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR CDX2; VILLIN; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; MLH1 PROTEIN, HUMAN; NRAS PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; RAS PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER;

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COLON CANCER; COLON MEDULLARY CARCINOMA; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MEDULLARY CARCINOMA; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYROSEQUENCING; ADENOCARCINOMA; ADULT; AGED; CARCINOMA, MEDULLARY; COLONIC NEOPLASMS; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; EVALUATION STUDY; GENETICS; METABOLISM; MIDDLE AGED; MOLECULAR DIAGNOSIS; MUTATION; OBSERVER VARIATION; PROCEDURES; VERY ELDERLY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, MEDULLARY; COLONIC NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; NUCLEAR PROTEINS; OBSERVER VARIATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84925532895     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-014-1675-6     Document Type: Article

References (31)

1. Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11.[Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr. Accessed 1 July 2014.
2. Thirunavukarasu P, Sathaiah M, Singla S et al (2010) Medullary carcinoma of the large intestine: a population based analysis. Int J Oncol 37(4)
3. Danish Colorectal Cancer Group, Annual Report 2012. Available at: http://dccg.dk. Accessed 1 July 2014
4. Hamilton SR, Bosman FT, Boffeta P et al (2010) Carcinoma of the colon and rectum. In: Bosman FT, Carneiro F, Hruban RH et al, eds. WHO Classification of Tumours of the Digestive System. Lyon: International Agency for Research on Cancer; 131–182
5. Jesserun J, Romero-Guadarrama M, Manivel J (1999) Medullary adenocarcinoma of the colon: clinicopathologic study of 11 cases. Hum Pathol 30(7):843–848
6. Sugao Y, Yao T, Kubo C et al (1997) Improved prognosis of solid-type poorly differentiated colorectal adenocarcinoma: a clinicopathological and immunohistochemical study. Histopathology 31:123–133
7. Wick MR, Vitsky JL, Ritter JH et al (2005) Sporadic medullary carcinoma of the colon: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma. Am J Clin Pathol 123:56–65
8. Winn B, Tavares R, Fanion J et al (2009) Differentiating the undifferentiated: immunohistochemical profile of medullary carcinoma of the colon with an emphasis on intestinal differentiation. Hum Pathol 40:398–404
9. Arai T, Esaki Y, Sawabe M et al (2004) Hypermethylation of the hMLH1 promoter with absent hMLH1 expression in medullary-type poorly differentiated colorectal adenocarcinoma in the elderly. Mod Pathol 17:172–179
10. Lanza G, Gafa R, Matteuzzi M et al (1999) Medullary-type poorly differentiated adenocarcinoma of the large bowel: a distinct clinicopathologic entity characterized by microsatellite instability and improved survival. J Clin Oncol 17:2429–2438
11. Rüschoff J, Dietmaier W, Lüttges J et al (1997) Poorly differentiated colonic adenocarcinoma medullary type. Am J Pathol 150:1815–1825
12. Alexander J, Watanabe T, Wu TT et al (2001) Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 158:527–535
13. Hinoi T, Tani M, Lucas PC et al (2001) Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol 159:2239–2248
14. Winn B, Tavares R, Matoso A et al (2010) Expression of the intestinal biomarkers guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas. Hum Pathol 41:123–128
15. Hansen TP (2002) Immunohistochemical tumor markers in colorectal cancer: a methodological and prognostic study. University of Southern Denmark, Odense
16. Smith DH, Fiehn AM, Fogh L et al (2014) Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody. Sci Rep 4:4313
17. Kim JH, Rhee YY, Bae JM et al (2013) Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer. Am J Surg Pathol 37:1532–1541
18. Xiao H, Yoon YS, Hong SM et al (2013) Poorly differentiated colorectal cancers: correlation of microsatellite instability with clinicopathologic features and survival. Am J Clin Pathol 140:341–347
19. Chetty R, Govender D (2013) Gene of the month: KRAS. J Clin Pathol 1–3
20. Herreros-Villanueva M, Chen CC, Yuan SS et al (2014) KRAS mutations: analytical considerations. Clin Chim Acta 431C:211–220
21. Vogelstein B, Fearon ER, Hamilton SR et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532
22. Patel GS, Karapetis CS (2013) Personalized treatment for advanced colorectal cancer: KRAS and beyond. Cancer Manag Res 5:387–400
23. Chen D, Huang JF, Liu K et al (2014) BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One 9:e90607
24. Cunningham D, Atkin W, Lenz HJ et al (2010) Colorectal cancer. Lancet 375:1030–1047
25. Govender D, Chetty R (2012) Gene of the month: BRAF. J Clin Pathol 65:986–988
26. Kim ST, Park KH, Shin SW et al (2014) Dose KRAS mutation status affect on the effect of VEGF therapy in metastatic colon cancer patients? Cancer Res Treat 46:48–54
27. Bertagnolli MM, Niedzwiecki D, Compton CC et al (2009) Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 27:1814–1821
28. Zaanan A, Flejou JF, Emile JF et al (2011) Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Clin Cancer Res 17:7470–7478
29. Jacquemier J, Reis-Filho JS, Lakhani SR et al (2012) Carcinomas with medullary features. In: Lakhani SR, Ellis IO, Schnitt SJ et al, eds. WHO Classification of Tumours of the Breast. Lyon: International Agency for Research on Cancer; 46–47
30. Longacre TA, Ennis M, Quenneville LA et al (2006) Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Mod Pathol 19:195–207
31. Park I, Kim J, Kim M et al (2013) Comparison of the characteristics of medullary breast carcinoma and invasive ductal carcinoma. J Breast Cancer 16:417–425